Abstract
Systemic therapy of breast cancer was introduced in 1896 by means of surgical ovariectomy [1]. Endocrine treatment is now widely accepted in advanced breast cancer with positive oestrogen or progesterone receptor status indicating endocrine dependency of the disease. Tamoxifen has been the treatment of choice for more than twenty years, due to it's favourable efficacy/tolerability ratio [2]. Several years ago, the third generation aromatase inhibitors have been introduced in the clinics [3]. Anastrozole is a potent selective non-steroidal aromatase inhibitor which can be administered orally as a once daily dose.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
